IA Mayer

452 citations
27 papers · 304 · h-index 9

Impact in

Papers in

  • Pulmonary and Respiratory Medicine 22
    • Advanced Breast Cancer Therapies 19
    • Lung Cancer Treatments and Mutations 2
  • Oncology 21
    • Cancer Treatment and Pharmacology 14
    • HER2/EGFR in Cancer Research 10
    • Cancer-related Molecular Pathways 2
Co-authors
Dejan Juric (8 shared papers)Aditya Bardia (9 shared papers)R Moroose (4 shared papers)Linda T. Vahdat (4 shared papers)Jennifer R. Diamond (4 shared papers)Joyce O’Shaughnessy (4 shared papers)Kevin Kalinsky (5 shared papers)William A. Wegener (1 shared paper)
Journals
Cancer Research (22 papers)Annals of Oncology (2 papers)ESMO Open (1 paper)European Journal of Cancer (1 paper)Journal of Clinical Oncology (1 paper)
Partner nations
United StatesFranceSwitzerland

In The Last Decade

IA Mayer

25 papers receiving 301 citations

Peers

IA Mayer
Comparison fields: 5 of 27
  • Oncology 207
  • Pulmonary and Respiratory Medicine 144
  • Cancer Research 60
  • Genetics 37
  • Radiology, Nuclear Medicine and Imaging 36
Replace Tong Luo with:
Tong Luo United States
SA Hurvitz United States
Kevin Chau United States
Hiroji Iwata Japan
Lori Marini United States
SM Tolaney United States
C. Saura Manich Spain
G. Lieberman United States
Markéta Palácová Czechia
Małgorzata Foszczyńska‐Kłoda Poland
IA Mayer relative to Tong Luo United States Tong Luo's profile →
Citations per field
00.5×1.5×
Tong Luo · 1×
Citations per year

Countries citing papers authored by IA Mayer

Since Specialization
Citations

This map shows the geographic impact of IA Mayer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by IA Mayer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites IA Mayer more than expected).

Fields of papers citing papers by IA Mayer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by IA Mayer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by IA Mayer. The network helps show where IA Mayer may publish in the future.

Co-authors

The 25 scholars most cited alongside IA Mayer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with IA Mayer Line = papers co-authored together IA Mayer links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 27 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial
Annals of Oncology ·Kevin Kalinsky, Jennifer R. Diamond, Linda T. Vahdat, Sara M. Tolaney, Dejan Juric, Joyce O’Shaughnessy, R Moroose, IA Mayer, Vandana G. Abramson, David M. Goldenberg, Robert M. Sharkey, Pius Maliakal, Q. Hong, Trishna Goswami, William A. Wegener, Aditya Bardia
2020116
2
Abstract GS3-08: Alpelisib + fulvestrant for advanced breast cancer: Subgroup analyses from the phase III SOLAR-1 trial
Cancer Research ·Dejan Juric, Eva Ciruelos, Gábor Rubovszky, Mario Campone, Sibylle Loibl, HS Rugo, Hiroji Iwata, PierFranco Conte, IA Mayer, Bella Kaufman, Toshinari Yamashita, Yen‐Shen Lu, Kenichi Inoue, Masanori Takahashi, Zsuzsanna Pápai, A-S. Longin, David Mills, C. Wilke, Dalila Sellami, Fabrice André
201946
3
Abstract P3-14-01: Phase Ib/II study of ribociclib and alpelisib and letrozole in ER+, HER2– breast cancer: Safety, preliminary efficacy and molecular analysis
Cancer Research ·Dejan Juric, Roohi Ismail‐Khan, Mario Campone, Laura García‐Estévez, Carlos Becerra, R. de Boer, Erika Hamilton, IA Mayer, Rina Hui, KI Lathrop, Olivia Pagani, S. Asano, SG Bhansali, V Zhang, Becker Hewes, P.N. Munster
201631
4
A Phase Ib Trial of RAD001, an mTOR Inhibitor, with Weekly Cisplatin and Paclitaxel in Patients with HER2-Negative Metastatic Breast Cancer.
Cancer Research ·IA Mayer, Howard A. Burris, Johanna C. Bendell, Julie Means‐Powell, CL Arteaga, Yu Shyr, JA Pietenpol
200916
5
Abstract GS1-07: Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate, as ≥3rd-line therapeutic option for patients with relapsed/refractory metastatic triple-negative breast cancer (mTNBC): efficacy results
Cancer Research ·Aditya Bardia, Linda T. Vahdat, Jennifer R. Diamond, Kevin Kalinsky, Joyce O’Shaughnessy, R Moroose, SJ Isakoff, SM Tolaney, AD Santin, V Abramson, NC Shah, SV Govindan, Paul Maliakal, RM Sharkey, WA Wegener, D M Goldenberg, IA Mayer
201812
6
Abstract GS6-05: Gain-of-function kinase library screen identifies FGFR1 amplification as a mechanism of resistance to antiestrogens and CDK4/6 inhibitors in ER+ breast cancer
Cancer Research ·Luigi Formisano, Yao Lu, VM Jansen, J Bauer, Ariella B. Hanker, (unknown), (unknown), M.W. Nixon, AL Guerrero-Zotano, LJ Schwarz, Melinda E. Sanders, Dhivya R. Sudhan, TC Dugger, MR Cruz, Amir Behdad, M Cristofanilli, Aditya Bardia, J. O’Shaughnessy, IA Mayer, CL Arteaga
201811
7
Abstract OT3-2-07: Phase I study of ARN-810, a novel selective estrogen receptor degrader, in post-menopausal women with locally advanced or metastatic estrogen receptor positive breast cancer
Cancer Research ·IA Mayer, Aditya Bardia, MN Dickler, H. Charles Manning, Umar Mahmood, GA Ulaner, JH Hager, Peter J. Rix, N Zack, EC Maneval, I Chen, José Baselga, CL Arteaga
201311
8
Abstract PD1-6: A randomized phase II neoadjuvant study of cisplatin, paclitaxel with or without everolimus (an mTOR inhibitor) in patients with stage II/III triple-negative breast cancer (TNBC)
Cancer Research ·IA Mayer, Bojana Jovanović, V Abramson, EL Mayer, ME Sanders, Aditya Bardia, P. Dillon, MG Kuba, J. Carpenter, Jae C. Chang, BD Lehmann, IM Meszoely, AM Grau, Yu Shyr, CL Arteaga, X Chen, JA Pietenpol
201311
9
Abstract P2-14-04: A Phase Ib Dose Escalation Trial of RO4929097 (a γ-secretase inhibitor) in Combination with Exemestane in Patients with ER + Metastatic Breast Cancer.
Cancer Research ·JA Means-Powell, S. E. Minton, IA Mayer, V Abramson, Roohi Ismail‐Khan, CL Arteaga, DA Ayers, MS Sanders, R. Lush, Lucio Miele
201210
10
PD09-05: SU2C Phase Ib Study of pan-PI3K Inhibitor BKM120 Plus Aromatase Inhibitor Letrozole in ER+/HER2− Metastatic Breast Cancer (MBC).
Cancer Research ·IA Mayer, Justin M. Balko, MG Kuba, ME Sanders, Jeffrey T. Yap, Y Li, E. Samuel Winer, CL Arteaga
20117
11
Abstract P4-22-18: Phase Ib safety, efficacy, and molecular analysis of ribociclib (LEE011) plus letrozole for the treatment of ER+, HER2– advanced breast cancer
Cancer Research ·Pamela N. Münster, Roohi Ismail‐Khan, Laura García‐Estévez, IA Mayer, Carlos Becerra, Erika Hamilton, R. de Boer, Andrew Wardley, S-A. Im, Luís Teixeira, Yu Wang, Fei Su, Caroline Germa, Samit Hirawat, Dejan Juric
20174
12
PD09-06: Phase II Trial of RAD001 (Everolimus), an mTOR Inhibitor, with Weekly Cisplatin and Paclitaxel in Patients with HER2−Negative Metastatic Breast Cancer (MBC).
Cancer Research ·IA Mayer, Julie Means‐Powell, V Abramson, Yu Shyr, Justin M. Balko, MG Kuba, HM Gharavi, Larry Schlabach, CL Arteaga, JA Pietenpol
20114
13
Abstract OT3-05-09: A randomized phase II trial of fulvestrant with or without ribociclib after progression on aromatase inhibition plus cyclin-dependent kinase 4/6 inhibition in patients with unresectable or metastatic hormone receptor positive, HER2 negative breast cancer (Maintain trial)
Cancer Research ·Kevin Kalinsky, PS Mundi, Codruța Chiuzan, MK Accordino, MS Trivedi, JA Sparano, SY Oh, Amy Tiersten, R O'Regan, Francisco J. Esteva, Suneil Jain, IA Mayer, Andres Forero, Christos Vaklavas, L. Baer, Katherine D. Crew, DL Hershman
20183
14
Abstract P2-11-01: Safety and efficacy of sacituzumab govitecan (anti-Trop-2-SN-38 antibody-drug conjugate) as ≥3rd-line therapeutic option for treatment-refractory HER2-negative metastatic breast cancer (HER2Neg mBC)
Cancer Research ·Kevin Kalinsky, SJ Isakoff, SM Tolaney, Dejan Juric, IA Mayer, Linda T. Vahdat, Jennifer R. Diamond, Joyce O’Shaughnessy, R Moroose, AD Santin, NC Shah, V Abramson, D M Goldenberg, RM Sharkey, SA Washkowitz, WA Wegener, Raffaele Iannone, Aditya Bardia
20193
15
OT3-02-04: TBCRC 012: ABCDE, a Phase II Randomized Study of Adjuvant Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise after Preoperative Chemotherapy for Breast Cancer.
Cancer Research ·EL Mayer, JA Ligibel, HJ Burstein, J Peppercorn, KD Miller, LA Carey, MN Dickler, IA Mayer, Andres Forero, Jennifer Eng‐Wong, PJ Pletcher, Nicole Ryabin, Rebecca Gelman, Antonio C. Wolff, EP Winer
20113
16
1977 Synergy of LCL161, an antagonist of inhibitor of apoptosis proteins (IAPs), with paclitaxel in a gene expression signature-enriched cohort of triple-negative breast cancer (TNBC)
European Journal of Cancer ·Aditya Bardia, Jacquelyn Cameron, Krishnaraju Venkatesan, D Robinson, D. Porter, S.B. Kim, Marina Parton, Sherko Kümmel, (unknown), Chiun‐Sheng Huang, J. Cortés Castán, Manuel Ruíz‐Borrego, ML Telli, Paloma Martín-Martorell, Robert Lopez, Julia Beck, Roohi Ismail‐Khan, S.C. Chen, Sara A. Hurvitz, IA Mayer
20153
17
A pilot feasibility study of gefitinib (ZD1839) and celecoxib in metastatic GI tumors
Journal of Clinical Oncology ·Nobuyuki Yamaguchi, IA Mayer, A. Malzyner, Carlos José Coelho de Andrade, A.M. Murad, A. Del Giglio, Henrique J. Cardoso
20043
18
Abstract P3-07-41: Genomic alterations indicative of a luminal A subtype associate with clinical benefit to buparlisib and letrozole in endocrine-resistant ER+/HER2– metastatic breast cancer
Cancer Research ·Justin M. Balko, Mellissa Hicks, MF Berger, D. Solit, Nancy Bouvier, ME Sanders, MV Estrada, HS Won, LC Cantley, IA Mayer, CL Arteaga
20162
19
258P Analysis of patients (pts) without an initial triple-negative breast cancer (TNBC) diagnosis (Dx) in the phase III ASCENT study of sacituzumab govitecan (SG) in brain metastases-negative (BMNeg) metastatic TNBC (mTNBC)
Annals of Oncology ·Joyce O’Shaughnessy, Adam Brufsky, Hope S. Rugo, Sara M. Tolaney, Sami Diab, Kevin Punie, Sagar Sardesai, E.P. Hamilton, Delphine Loirat, TA Traina, RA Leon-Ferre, Sara A. Hurvitz, Kevin Kalinsky, Aditya Bardia, Stéphanie Henry, IA Mayer, Quan Hong, S. Phan, Javier Cortés
20212
20
Abstract P6-10-05: SU2C Phase 1b Trial of Dual PI3K/ mTOR Inhibitor BEZ235 with Letrozole in ER+/HER2− Metastatic Breast Cancer (MBC)
Cancer Research ·IA Mayer, V Abramson, Justin M. Balko, SJ Isakoff, Andres Forero, MG Kuba, ME Sanders, Y Li, Eric P. Winer, CL Arteaga
20121

About IA Mayer

IA Mayer is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Molecular Biology, Cancer Research and Radiology, Nuclear Medicine and Imaging, having authored 27 papers that have together received 304 indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (19 papers), Cancer Treatment and Pharmacology (14 papers), HER2/EGFR in Cancer Research (10 papers), PI3K/AKT/mTOR signaling in cancer (7 papers), Cancer Genomics and Diagnostics (4 papers), Estrogen and related hormone effects (2 papers), Cancer-related Molecular Pathways (2 papers) and Lung Cancer Treatments and Mutations (2 papers). The work is most often cited by research in Oncology (207 citations), Pulmonary and Respiratory Medicine (144 citations), Cancer Research (60 citations), Genetics (37 citations) and Radiology, Nuclear Medicine and Imaging (36 citations). IA Mayer has collaborated with scholars based in United States, France and Switzerland. Frequent co-authors include Dejan Juric, Aditya Bardia, R Moroose, Linda T. Vahdat, Jennifer R. Diamond, Joyce O’Shaughnessy, Kevin Kalinsky, William A. Wegener, Q. Hong and Pius Maliakal. Their work appears in journals such as Cancer Research, Annals of Oncology, ESMO Open, European Journal of Cancer and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tong LuoBreakdown of academic impact, for papers by SA HurvitzBreakdown of academic impact, for papers by Kevin ChauBreakdown of academic impact, for papers by Hiroji IwataBreakdown of academic impact, for papers by Lori MariniBreakdown of academic impact, for papers by SM TolaneyBreakdown of academic impact, for papers by C. Saura ManichBreakdown of academic impact, for papers by G. LiebermanBreakdown of academic impact, for papers by Markéta PalácováBreakdown of academic impact, for papers by Małgorzata Foszczyńska‐Kłoda